Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y. C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B. C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A.

Published in

Elsevier, European Journal of Cancer, (174), p. S75-S76, 2022

DOI: 10.1016/s0959-8049(22)01000-0

Tools

Export citation

Search in Google Scholar

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

Journal article published in 2022 by B. Besse, C. Springfeld, C. Baik, A. Hervieu, B. Solomon, V. Moreno, L. Bazhenova, K. Goto, Y. C. Kim, S. Lu, M. Sun, D. Trone, S. Thamake, B. C. Cho

, A. de Langen and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)